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ABSTRACT Seaweeds and soy are two commonly eaten foods in Asia. Both have been reported to affect thyroid function,
seaweed because of its iodine content and soy because of its goitrogenic effect. Twenty-five healthy postmenopausal women
(mean age 58 years) completed a double-blinded randomized crossover study. Ten capsules (5 g/day) of placebo or seaweed
(Alaria esculenta), providing 475 g of iodine/day, were consumed daily for 7 weeks. A powdered soy protein isolate (So-
lae Co., St. Louis, MO), providing 2 mg of isoflavones/kg of body weight, was given daily during the last week of each treat-
ment arm. On average, this provided 141.3 mg of isoflavones/day and 67.5 g of protein/day. Blood samples and 48-hour urine
samples were collected before and after each intervention period, and urinary I/C (g of iodine/g of creatinine) and serum
thyroxine, free thyroxine index, total triiodothyronine, and thyroid stimulating hormone (TSH) were measured. Seaweed in-
gestion increased I/C concentrations (P  .0001) and serum TSH (P  .0001) (1.69  0.22 vs. 2.19  0.22 U/mL, mean 
SE). Soy supplementation did not affect thyroid end points. Seven weeks of 5 g/day seaweed supplementation was associated
with a small but statistically significant increase in TSH. Soy protein isolate supplementation was not associated with changes
in serum thyroid hormone concentrations.




SEAWEEDS ARE PART of many indigenous cuisines aroundthe world, and have been incorporated into some heal-
ing therapies, including traditional Chinese medicine,
Ayurveda, and modern macrobiotics, as well as many folk
medicines. On a population level, those people for whom
seaweed is a regular part of their diet, most notably in Japan,
have dramatically lower breast cancer and prostate cancer
rates.1–3 Epidemiologic studies done in the 1980s, before
Westernized diets were common, found that Japanese
women had one-third the rate of premenopausal breast can-
cer and one-ninth the rate of postmenopausal breast cancer.4
In addition, when a Japanese woman developed breast can-
cer, she was more likely to survive at least 5 years longer
than women with breast cancer in the United States.5,6 The
histologic type of breast cancer also varies by country, with
Japanese women having greater humoral immune responses
to the tumors as suggested by the greater degree of lym-
phocytic invasion of their breast tumors.5
No previous intervention studies have combined seaweed
and soy, but epidemiologic evidence suggests that this com-
bination could be anticarcinogenic. Consumption of miso
soup has been associated with reduced breast cancer rates.7–9
Miso soup is usually a combination of soy (miso, tofu cubes)
and seaweed (as a stock flavoring and as garnish), and some-
times vegetables.
Seaweed is not necessarily a safe food to consume. We
have reported elsewhere that commonly consumed seaweeds
have a wide range of iodine concentrations, i.e., between 16
g/g and 8,000 g/g,10 making iodine an important dose-
limiting factor in seaweed consumption, particularly for peo-
ple not accustomed to eating seaweed.11 The lowest-ob-
served-adverse-effect level, based on increases in serum
thyroid stimulating hormone (TSH) in thyroid function chal-
lenge tests, is 1,700 g/day (U.S. and Canadian RDI Com-
mittee).12 However, habituation to high iodine-containing
seaweeds appears to be common in Asia, particularly Japan,
Korea, and coastal China, where seaweeds are frequently
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eaten and appear to be well tolerated by millions of people.
The average seaweed intake in Japan is approximately 4–7
g/day,13–15 with some estimates as high as 10 g per person
per day.16 It is difficult to quantify the actual amount of sea-
weed consumed as it is often added as flavoring to noodles,
soups, and garnishes and may be served as a snack, salad,
or side dish. Based on dietary intake surveys, the average
daily iodine intake in these regions is between 500 and 1,000
g/day (ranging from 200 to 20,000 g/day), with most of
the dietary iodine coming from seaweed consumption.16
For this study, we chose a low-iodine-containing seaweed
(Alaria esculenta) to approximate the Japanese average sea-
weed intake, rather than the approximate iodine intake.
Soyfoods have been suggested as possible human goitro-
gens.17 The dose of soy protein in our study (average 67.5
g/day) was based on early estimates of average total soy in-
take in Japan.18 More recent dietary studies indicated that
the soy protein intake in Japan is actually lower (10 g/day).
The present study determined whether iodine in seaweed
was bioavailable and would affect thyroid function, whether
a short-term soy protein isolate supplementation would af-
fect thyroid function, and whether consumption of these two
foods together would have any discernible effect on thyroid
function that might be clinically important. Individual con-
trasts were created to test three hypotheses: (1) was seaweed
different from placebo (seaweed main effect), (2) was soy
different from placebo (soy main effect), and (3) was there
an effect from combining seaweed and soy that was differ-
ent from the additive effects of seaweed plus soy (seaweed
soy interaction)? Since the greatest difference between U.S.
and Japanese breast cancer rates begins at about age 45
years,19 we studied only postmenopausal women.
SUBJECTS AND METHODS
Study population
The University of Massachusetts Medical School Institu-
tional Review Board approved the study. Consent forms
were reviewed verbally, and all participants gave written in-
formed consent.
Participants were a group of Caucasian American women
living in central Massachusetts. We specifically recruited
healthy postmenopausal women who had been treated for
early breast cancer and women who had never had breast
cancer. Women were recruited by word of mouth, by physi-
cians, and through responses to an article in the newspaper.
Our inclusion criteria included being postmenopausal (no
bleeding for at least 1 year), intact ovaries at the time of
menopause, no history of cancer (other than early breast can-
cer), no thyroid dysfunction or treatment within the previ-
ous 5 years, negative thyroid peroxidase antibodies exclud-
ing Hashimoto’s thyroiditis, no hormone replacement
therapy within the previous 3 years, no ulcer medications or
lithium-based medications, no gastrointestinal disorders
such as Crohn’s disease or irritable bowel syndrome, no al-
lergies to seaweed, soy, shellfish, or iodine, no treatment
with oral antibiotics, iodine-containing medications, or cor-
ticosteroids within the previous 3 months, no diabetes, and
no high blood pressure medications. In addition, only non-
vegetarian women who consumed soy products fewer than
two times per week were eligible. Women agreed to avoid
eating soy foods during the study, including soybeans and
soy products, as well as sprouts, beans, peas, and lentils, and
to restrict alcoholic intake to one or fewer drinks per week.
Although vitamin and supplement use was allowed, women
were asked to refrain from changing dosage or usage dur-
ing the study. Use of black cohosh, Dong Quai herbal sup-
plements, or yam cream was an additional reason for ineli-
gibility.
Forty-eight postmenopausal women were recruited.
Based on screening blood samples, we excluded 15 addi-
tional women, two for abnormal serum TSH values (either
0.4 or 4.5 U/mL TSH), three for elevated thyroid per-
oxidase antibodies, three for current or recent thyroid med-
ications, and seven for lack of interest. Thus, 33 women
were enrolled in the study and provided baseline data. Sub-
sequently, four women dropped out during the course of the
study because of a lack of interest (one), naturopath advice
(one), or allergic reaction (two). Of the two who developed
allergic reactions to seaweed, one had red itchy eyes, and
the other experienced re-activated esophageal reflux. Both
conditions resolved spontaneously following cessation of
seaweed intake. At the end of the study, two women were
excluded because one woman began menstruating again,
while the other failed to follow study protocol.
Following publication of studies during the trial on the
effects of tamoxifen/roloxifen on thyroid function,20–22 we
excluded the three women who used tamoxifen during the
entire study, and the one woman who started taking tamox-
ifen late in the trial had her last three observations omitted.
Her earlier measures were included in the analysis. This left
a final study sample of 25 women among whom 10 had a
history of early (Stage I or II) breast cancer but were dis-
ease free at the time of the study and 15 women who had
never been diagnosed with breast cancer.
Study design
The study utilized a randomized, placebo-controlled
crossover design. Women were randomized to either 6
weeks of 5 g/day seaweed powder (10 capsules) each
evening with the last meal of the day or 6 weeks of 5 g/day
maltodextrose in 10 identical gelatin capsules. For 1 addi-
tional week, women received either seaweed capsules or
placebo capsules and the high isoflavone powder. To mini-
mize possible effects of season, all women began the study
the same week in late October. Samples were collected a to-
tal of seven times (blood samples and 48-hour urine collec-
tions) throughout the study. A 3-week washout period sep-
arated the two arms of the study, and a final 3-week washout
period followed the end of the last supplements (Fig. 1).
Randomization was done using a computer-generated ran-
dom number table. In addition, to assure blinded laboratory
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analysis, each patient at each clinic visit was assigned a
unique ID number.
Seaweed
In order to ensure safe iodine exposure, seaweed sam-
ples were collected from seaweed harvesters and health
food stores for a preliminary survey of iodine analysis
(Fig. 2). For this study, we chose A. esculenta, also known
as American wakame, a low-iodine (95 g/g)-containing
seaweed. The A. esculenta was harvested at an extremely
low tide from the subtidal rocks of the Sally Islands, lo-
cated near Stuben, ME. The blades of Alaria were cut by
hand, placed in plastic baskets, and transported from the
islands to the shore in a separate boat made especially for
hauling seaweed, which was towed behind a larger boat.
No gasoline or other potentially toxic substances were
present in the seaweed barge. Within 1 hour of harvest-
ing, the seaweed fronds were hung on untreated wooden
racks to sun-dry. After about 10 hours in the sun, the
fronds were gathered in bundles, placed in plastic bags,
and stored at ambient room temperature in a dark room
until shipping, which was done within 2 months of 
harvest.
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FIG. 1. Study design.
FIG. 2. Comparison of iodine content of common dietary seaweeds.
Encapsulation
The seaweed was shipped by overnight mail to Beehive
Botanicals, a subsidiary of Twin Labs (Hayward, WI), where
it was tested for mold and fungus and found to be negative.
The seaweed was ground and encapsulated into gelatin 
capsules. No fillers or binders were added to the seaweed
powder.
Placebo
Maltrin M100 maltodextrin (Grain Processing Corp.,
Muscatine, IA) was used for placebo. The daily dose of 5
g/day provided 18 kcal of food energy. We used the same
capsules for maltodextrin and the seaweed. No fillers or
binders were added to the placebo powder.
Iodine content of finished capsules
Gelatin capsules were used and, when analyzed for io-
dine content, were found to contain no iodine. The finished
seaweed capsules were analyzed, and each capsule contained
47.5 g of iodine. Thus for our study, we provided an ad-
ditional 475 g of iodine/day.
Soy protein
Soy powder [Supro High Protein Nutritious Food Ingre-
dient Powder (with isoflavones)] (lot number G198–8) was
provided by Solae Co. (formerly Protein Technologies, Inc.,
St. Louis, MO). It contained 1.43 mg of total aglycone (un-
conjugated or free) isoflavone/g of soy powder. We calcu-
lated the appropriate dose for each subject based on her
weight, so that each woman consumed 2 mg of
isoflavones/kg of body weight. On average, each woman
was given 67.5 g/day of soy protein. This provided 141.3
mg/day isoflavones, 376 calories, 2.2 g of fat, and 22 g of
carbohydrates and supplied 539 g of calcium. Subjects were
advised to consume the soy protein isolate as a substitute
meal during the 2 weeks of soy supplementation.
Thyroid hormones
Chemiluminometric immunoassays (Chiron Diagnostics,
East Walpole, MA) were used to measure serum TSH, tri-
iodothyronine (T3), thyroxine (T4), and T3 resin uptake
[thyroid hormone-binding ratio (THBR)]. The free T4 index
(FTI) was calculated as the product of THBR  T4. A
chemiluminometric enzyme-linked immunosorbent assay
was used to measure anti-thyroid peroxidase antibody
(ALPCO, American Laboratory Products Co., Wyndham,
NH) and was sensitive to 5 IU/mL. All of these assays and
urinary creatinine were measured by the Endocrine-Hyper-
tension Laboratory at the Brigham & Women’s Hospital,
Boston, MA.
Iodine
Iodine in urine, empty capsules, and finished capsules was
analyzed using the ceric-arsenic redox reaction. Samples
were analyzed according to standard determination of total
iodine protocol as outlined by Benotti et al.23 This used the
reduction-oxidation reaction between ceric and arsenite cat-
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TABLE 1. DEMOGRAPHIC FACTORS FOR 25 WOMEN
Breast cancer Disease free
Characteristic Number % Number % P value
Education 0.58a
High school graduate or less 2 20 4 27
Some college or associate degree 4 40 3 20
Bachelors degree or more 4 40 8 53
Ethnicity
Caucasian American 10 100 15 100 —
Social status 0.36a
Living alone 3 30 2 13
Living with someone 7 70 13 87
Employment 0.83a
Full-time 7 70 9 60
Part-time 1 10 1 7
Not working 2 20 5 33
Mean SD Mean SD
Age (years) 58.4 6.1 58.1 8.5 0.93b
BMI (kg/m2) 27.2 6.7 26.2 4.4 0.66b
This analysis includes 25 women, 10 with a history of breast cancer and 15 with no such history.
aBy Fischer’s exact test.
bBy t test.
alyzed by iodide. The iodine concentration was proportional
to its catalytic activity. First, iodine was precipitated with
perchloric acid, and the samples were digested with chloric
acid. They were then measured spectrometrically at 420 nm
(Autoanalyzer, Technicon Instrument, Inc., Tarrytown, NY).
Calculations were based on an iodine standard curve. The
urine results were calculated as g of iodine/dL, per g of
creatinine, or total urinary iodine/day.
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TABLE 2. LIFE-STYLE- AND HEALTH-RELATED FACTORS FOR 25 WOMEN
Breast cancer Disease free
Characteristic Number % Number % P value
General health 0.72a
Excellent 2 20 5 33
Very good 6 60 9 60
Good 2 20 1 7
Exercise 0.12a
Yes 5 50 12 80
No 5 50 3 20
Alcohol useb 0.67a
Yes 4 40 4 27
No 6 60 11 73
Multivitamin use 0.69a
Yes 6 60 7 47
No 4 40 8 53
Herbal supplements use 1.00a
Yes 4 40 7 47
No 6 60 8 53
Hysterectomy 0.27a
Yes 3 30 1 7
No 7 70 14 93
Ever pregnant 1.00a
Yes 9 90 13 87
No 1 10 2 13
Menopausal symptoms 0.24a
Yes 6 60 5 33
No 4 40 10 67
Self-medication for menopausal symptomsc 1.00a
Yes 3 30 5 33
No 7 70 10 67
Family history of breast cancer
Yes 2 20 10 67 0.04a
No 8 80 5 33
If yes, first-degree breast cancer 0.45a
Not applicable 8 — 5 —
Yes 1 50 8 80
No 1 50 2 20
If first-degree, breast cancer type 1.00a
Premenopausal 0 0 1 13
Postmenopausal 1 100 7 87
Not applicable 8 — 5 —
Missing 1 — 2 —
Mean SD Mean SD
Age at first pregnancy 24.2 3.4 24.3 3.7 0.24d
Age (years) at menopause 48.8 3.5 50.5 2.2 0.15d
Social supporte 17.9 9.9 13.1 9.4 0.24d
Number of miscarriages 0.9 1.4 0.4 0.8 0.28d
This analysis includes 25 women, 10 with a history of breast cancer and 15 with no such history.
aBy Fischer’s exact test.
bOne or fewer drinks per week.
cSelf-medication of menopausal symptoms with dietary herbal supplements, or over-the-counter drugs.
dBy t test.
eSocial support was defined as the number of friends and relatives a woman was in contact with during a week.
Urine collection
Women collected 48-hour urine specimens in 3-L con-
tainers to which 3 g of ascorbic acid powder had been added.
Women stored the collection jugs in their refrigerators un-
til they came in for their next clinic visit (within a day of
the end of the collection period). After the contents of the
jugs were completely mixed, aliquots were taken and stored
at 20°C until analysis.
Statistical analyses
Analyses were conducted on 25 women using an inten-
tion-to-treat approach. The study sample characteristics are
presented using descriptive statistics. To test the main study
hypotheses, a repeated-measures analysis of variance was
conducted using Proc Mixed in SAS (SAS, Cary, NC).24 In
these models, subject was fit as the repeated factor, while
the independent variables treatment group (placebo, sea-
weed, soy, and seaweed plus soy), treatment arm (treatment
followed by placebo or placebo followed by treatment), and
disease status (history of breast cancer: yes or no) were fit
as independent variables. Individual models were run for
seven dependent variables: serum total T3, T4, FTI, TSH,
and urinary iodine (24-hour excretion, concentration/dL, and
iodine standardized per g of creatinine). Results are pre-
sented as both average concentrations (SD) and least
squares means, and the differences are tested using the pdiff
option of the Proc Mixed procedure.
RESULTS
The demographic and life-style characteristics of the 25
subjects are presented in Tables 1 and 2. The only signifi-
cant difference between the women who had been treated
for breast cancer and those who had never had breast can-
cer was in family history. Although we had expected that
women with breast cancer would have a stronger family his-
tory of breast cancer, that was not the case in our study.
Two-thirds of the control women had a family history of
breast cancer compared to only 20% of the breast cancer pa-
tients (P  .04), although there was no difference between
groups in number of first-degree relatives who had been di-
agnosed with breast cancer.
There were no differences in thyroid function during sea-
weed and/or soy ingestion between the women who had been
treated for early breast cancer but were disease free com-
pared to women who never had breast cancer.
Table 3 presents average serum measurements of thyroid
function and urinary iodine excretion in each treatment
group. The only significant effects were that seaweed
markedly increased urinary iodine excretion and slightly in-
creased serum TSH (Table 3 and Fig. 3). These seaweed ef-
fects were not altered by soy ingestion.
Because the within-subject variation in 24-hour urinary
creatinine excretion averaged 15% (median 13%), we were
concerned that urine collections may have been incomplete
for some subjects. Data were analyzed using urinary iodine/g
of creatinine concentration, urinary iodine concentration
(g/dL), and total 24-hour urinary iodine (I/day) excretion.
The statistical results did not vary, suggesting that our abil-
ity to estimate treatment effects was not affected by this fac-
tor. Soy protein isolate supplementation had no significant
effect, and there was no evidence that there was an interac-
tion between seaweed and soy, when administered together.
Body mass index (BMI) of the women varied from 18 to
44 kg/m2. We found no treatment-by-BMI interaction, and
although there was a marginally significant association be-
tween weight and TSH, there was no evidence that it influ-
enced our estimation of the seaweed effect.
DISCUSSION
Our data support our first hypothesis that seaweed con-
tains bioavailable iodine, and that consuming seaweed sup-
plements would affect thyroid function. The changes were
small, and although statistically significant for an increase
in serum TSH, the values remained well within normal
ranges and were unlikely to be physiologically important.
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TABLE 3. MEAN VALUES FOR THYROID FUNCTION AND URINARY IODINE EXCRETION BY TREATMENT PERIOD FOR 25 WOMEN
Placebo Seaweed Soy Seaweed and soy
Thyroid tests Mean SD Mean SD Mean SD Mean SD
Serum hormones
T3 (ng/dL) 124.1 16.5 128.4 16.2 125.6 17.7 125.8 16.6
T4 (g/dL) 6.6 1.0 6.6 0.9 6.8 1.1 6.7 0.8
FTI 5.7 0.7 5.8 0.7 5.9 0.9 5.9 0.7
TSH (IU/mL) 1.69 0.95 2.19** 1.23 1.64 1.01 1.94** 1.13
Urinary iodine excretion
Iodine (g/day) 265.8 155.8 567.8** 177.8 290.5 190.9 545.6** 136.7
Iodine (g/g of creatinine) 290.5 147.8 586.9** 177.6 328.5 185.4 571.7 147.8
Iodine (g/dL) 13.5 7.8 31.5** 12.3 115.0 12.2 28.7 8.2
This analysis includes 25 women, 10 with a history of breast cancer and 15 with no such history. As this was a crossover study,
each woman received each treatment, and these values represent the average values in all 25 subjects.
**P  .01 versus placebo or soy alone.
However, some common dietary seaweeds, especially kelp
(Laminaria), can contain 40 times as much iodine. The small
changes we observed in euthyroid women may not be rep-
resentative of the effects of high-iodine kelp in the general
population.
Soy protein isolate supplementation has been associated
with goiter formation in iodine-deficient rats and hu-
mans.17,25 This does not appear to be the case in healthy
postmenopausal American women. In our study of iodine-
replete subjects, none of the women experienced clinically
significant changes in thyroid hormones or urinary excre-
tion of iodine during either of the two 1-week periods of
high isoflavone (average 141 mg of total isoflavones/day)
soy powder supplementation. Our adjusted dose of
isoflavones to body weight (2 mg of isoflavones/kg/day), re-
sulted in an average daily intake of 67.5 g of soy protein,
or about six to seven times the daily intake of soy protein
in Japan.26 The previous study by Bruce et al.27 of 38 healthy
postmenopausal women in a randomized double-blind
placebo-controlled study showed no effect of soy supple-
mentation on thyroid function in women given slightly less
(90 mg of total isoflavones/day) soy protein isolate and fol-
lowed for 6 months. Likewise, two other studies have in-
vestigated the longer-term effects of soy protein isolate on
thyroid function. Duncan et al.28 followed 18 post-
menopausal women given the same dose of soy protein iso-
late supplement (2 mg of isoflavones/kg/day) for 3 months
and found no change in thyroid hormone concentrations. In
contrast, Persky et al.29 studied 46 postmenopausal women
who consumed either a high (90 mg/day) isoflavone soy pro-
tein isolate (ISP 90, Protein Technologies) or moderate (56
mg/day) isoflavone (ISP56, Protein Technologies) for 6
months and reported small but statistically significant
changes in thyroid function. In these women, serum TSH
was significantly higher at 3 and 6 months in women in-
gesting ISP90, serum T4 was significantly higher in women
ingesting ISP56 at both 3 and 6 months, and serum T3 was
significantly higher at 6 months in the women ingesting
ISP90. However, it is difficult to interpret these findings
since the hormone values for the women in the three groups
(control, ISP56, and ISP90) differed at baseline. All values
remained the within normal ranges. Our results from two
separate 1-week exposures to high soy protein isolate pro-
vide additional support for the hypothesis that soy supple-
mentation in iodine-replete populations have minimal or no
effects on thyroid function.
On average, the women in our study excreted 266 g of
I/day (13 g/dL) during the control period and 587 g of
I/day (32 g/dL) while ingesting seaweed. Thus, our sub-
jects were iodine sufficient at the beginning of the study and
slightly above average for the United States.30 Exposure to
dietary iodine in Asia is much higher. For example, in Japan,
the mean urinary iodine excretion in apparently healthy men
and women in Sapporo was 5,100 g/day (n  4,138)31 and
211 g/dL in Korea (n  207),32 compared to a median of
approximately 217 g/day in 20,369 Americans.30 When
urinary iodine is standardized for creatinine content, the
women in our study excreted 291 g/g when ingesting
placebo and 587 g/g when ingesting seaweed. This is close
to 673 g/g of creatinine reported for 278 healthy adults in
Korea,33 where seaweed intake is common, and suggests that
our study used seaweed exposure that approximates that
found in Asia, where a variety of different kinds of seaweeds
are eaten daily in small amounts.
There have been two other studies confirming the
bioavailability of iodine from seaweed. Clark et al.34 con-
ducted a similar double-blind prospective 6-week clinical
trial in 36 healthy euthyroid subjects. The study utilized
commercial kelp tablets with an estimated 250 g per cap-
sule iodine content. Alfalfa (four capsules per day) was com-
pared with high-dose kelp (four capsules per day) and low-
dose kelp (two kelp capsules per day and two alfalfa capsules
per day). Similar to our study, TSH increased significantly
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FIG. 3. Comparison of treatment effects on the thyroid hormones




in both kelp-supplemented groups. Serum free T4 concen-
trations did not change with either kelp supplementation, but
total T3 did significantly after high-dose kelp; the latter find-
ing remains unexplained. Their low-dose kelp ingestion cor-
responded to that in the present study, and urine iodine ex-
cretion was similar. Unlike our study in which we observed
a slight but nonsignificant increase in T3, in the study by
Clark et al.,34 T3 decreased significantly after high-dose
kelp therapy.
In the second study of iodine bioavailability from sea-
weed, Aquaron et al.35 reported on the 48-hour short-term
effect of dietary seaweed in two different geographic loca-
tions. In 18 healthy iodine-replete volunteers in Marseille,
France, 90% of the seaweed iodine was excreted, but in a
mildly iodine-deficient population in Brussels, Belgium,
only 62% of the seaweed iodine was excreted in 48 hours.
In our study in an iodine-sufficient population, 60% of the
seaweed iodine was excreted in the urine. It is unclear why
this was the case. When we compared within-subject vari-
ation in total urinary creatinine content of the collection
specimens, the coefficient of variation averaged 15  7%,
with a range between 4% and 30%. We hypothesize that
some of the urine collections for some women at a few time
points may have been incomplete, possibly explaining the
lower percentage of excreted iodine observed in our iodine-
replete population.
In Japan and Korea, exposure to high iodine-containing
foods usually begins in utero and via breast milk.36 A study
of 50 lactating Korean mothers reported the average mater-
nal iodine intake immediately postpartum was 2,744 g/day,
decreasing to 1,295 g/day at 4 weeks. The iodine concen-
tration of the colostrum was 2,170 g/L, and breast milk at
4 weeks contained 892 g/L. This supports the possibility
that early exposure to high iodine may be important in the
habituation of people living in Asia to high ambient levels
of dietary iodine.
Even though we report a small rise in serum TSH with
moderate seaweed iodine exposure, thyroid disease in Japan
is less common than in the United States. The prevalence of
hyperthyroidism (TSH 0.15 U/L) among 4,110 people
living on Hokkaido in Japan was 0.6% among people liv-
ing in the capitol of Sapporo and 1.1% among people liv-
ing along the coast, with the latter presumably having more
seaweed in their diets.31 By comparison, the prevalence of
hyperthyroidism (TSH 0.1 U/L) among 13,344 adults
with no underlying thyroid problems in the United States
was 1.3%.37 A slightly more stringent definition of hyper-
thyroidism in the United States (0.1 U/L) than in Japan
(0.15 U/L) may partially explain the minor differences
in rates between the two countries. Hypothyroidism (TSH
5.0 U/L) prevalence in Japan was 1.3% in Sapporo and
3.8% along the coast.31 The U.S. prevalence of hypothy-
roidism (TSH 4.5 U/L) was 4.6%.37 Again, the slightly
different cutoff points may explain the greater prevalence in
the United States. Age-standardized incidence of thyroid
cancer rates are higher in the United States (6.2/100,000)
compared to Japan (4.8/100,000), but the death rates from
thyroid cancer are twice as high in Japan (0.6) as in the
United States (0.3).19 Using autopsy studies to estimate the
rate of undetected thyroid cancer at death, the prevalence in
Japan was 35%,38 compared to 3.6% in the United States.39
This high prevalence of occult thyroid tumors (35%) but un-
common clinical diagnosis (4.8 age-standardized rate) and
mortality (0.6 age-standardized rate) in Japan suggests that
factors such as diet or environment play a role in thyroid
cancer initiation and progression. People who immigrate
from Japan to the United States have higher rates of many
cancers, including thyroid cancer.40
The safety of high seaweed iodine supplements in the
United States, where people have not been exposed since
infancy, may be different than it is in Japan. Based on re-
views of thyroid status of people in the United States, be-
tween 9.5% to 24% of women older than 60 years of age
had evidence of thyroid dysfunction (TSH 5 mIU/L).37,41
Even among people known to have hypothyroidism, a re-
cent study found that 40% of people who were taking thy-
roid medications had elevated or suppressed serum TSH 
levels,41 suggesting poor patient compliance, inadequate su-
pervision, or variability in T4 content of the prescribed
tablets. These baseline characteristics of U.S. populations
suggest that low iodine-containing seaweeds would be safe,
but the more typical high iodine seaweeds (kelp) deserve
further study. Since older women have a high prevalence of
Hashimoto’s thyroiditis, which predisposes them to iodine-
induced hypothyroidism, or nodular goiter, predisposing
them to iodine-induced hyperthyroidism, careful monitoring
of thyroid function is advisable in iodine-exposed women
with positive thyroid antibodies or nodular goiter.42
With any dietary change there is the question of possible
harm. In addition to thyroid function, long-term exposure to
seaweed and thyroid cancer risk need to be considered. Re-
ports of an association between thyroid disease and breast
cancer have been found in some, but not all, epidemiologic
studies.43 In the largest case control study including 9,257
American women (4,575 cases and 4,682 controls), the only
significant association between thyroid disease and breast
cancer was that parous women who had been treated for thy-
roid cancer had an increased risk of breast cancer.44 Like-
wise, a large retrospective study of 41,686 breast cancer pa-
tients and 3,662 thyroid cancer patients seen at MD
Anderson Hospital reported a significantly increased risk of
developing breast cancer after thyroid cancer in young
women.45 This finding was explored further using the Na-
tional Cancer Institute’s Surveillance, Epidemiology and
End Results database with 1,333,115 person-years of data.
Women who were diagnosed with thyroid cancer had a sig-
nificantly increased risk of developing breast cancer. Again,
those who had been treated for thyroid cancer had an in-
creased risk of breast cancer (relative risk 1.18, P  .007).
The effect was most pronounced in premenopausal women
(relative risk 1.42, P  .001).46 It is possible that therapy of
thyroid cancer with large doses of 121I may play a role in
this association since the nonlactating breast weakly con-
centrates iodine.
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In a more general sense, the role of iodine, as opposed to
thyroid function, may be important, as there is some sug-
gestion that iodine deficiency is a risk factor for breast can-
cer.47–49 Iodine is critical for the health of newborn infants,
and during lactation and in rapidly dividing breast cancer
cells. These observations led to the identification of the
mammary gland iodide transporter (sodium iodide sym-
porter) protein,50 important in breast cell differentiation dur-
ing breast development. Additionally, therapeutic success
using oral iodine for breast fibrocystic disease has been re-
ported.51,52 Venuri47 hypothesized that iodine is a primitive
antioxidant that has been evolutionarily conserved, and pro-
vides protection to cell membranes. The form of iodine may
be particularly important for breast cancer. Aceves et al.53
have reviewed the literature of known effects of iodine on
breast cancer and concluded that in its oxidative form, it is
a potent antioxidant, inducing antiproliferative and apoptotic
actions via iodinated lipids called iodolactones. Potassium
iodine, as used in iodine supplementation programs, does
not have these effects. The in vivo data are also suggestive
of a role for seaweed iodine in mammary tissue protection.
Three studies by Funahashi and coworkers explored the re-
lationship of iodine and iodine in seaweed as factors in in-
hibition of 7,12-dimethylbenz[a]anthracene-induced mam-
mary tumors in rats.54–56 As a possible mechanism, they
reported a high correlation between serum iodine and apop-
tosis of mammary cancer cells. These results, along with
those we57 and others58–60 have reported for dietary seaweed
as inhibitory of 7,12-dimethylbenz[a]anthracene-induced
mammary tumors, are supportive of the idea that seaweed,
possibly via iodine, could be involved in breast cancer pre-
vention.
CONCLUSION
In an iodine-replete population of healthy postmenopausal
women with normal thyroid function, the ingestion of an ad-
ditional 475 g of I/day was associated with a small but sig-
nificant increase in serum TSH. Soy protein isolate had no
effect on thyroid function or iodine excretion. A history of
treatment for early breast cancer (Stage I or II) did not al-
ter the changes observed in the seaweed-associated increase
in TSH or iodine excretion. However, our sample size was
small, and all women in the present study were screened to
rule out underlying thyroid disease. It is unknown how sea-
weed ingestion might affect women with underlying thyroid
disease. Given appropriate medical supervision and prior
screening for allergies to iodine and thyroid function, con-
sumption of low iodine seaweed and soy protein isolate is
unlikely to cause serious side effects.
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